China’s 2026 National Reimbursement Drug List Adds Baili Tianheng’s EGFR×HER3 Bispecific ADC

TREE NEWS update: Baili Tianheng’s EGFR×HER3 bispecific antibody-drug conjugate Yizekang (iza-bren) was added to China’s 2026 National Reimbursement Drug List through national price negotiations, the list was announced on November 14 at the 2026 National Innovative Drug High-Quality Development Conference. The drug, the world’s first and only approved EGFR×HER3 bispecific ADC, entered reimbursement in its first year on the market under a new pre-declaration mechanism. The updated list takes effect January 1, 2027.